JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook
Jazz Pharmaceuticals (JAZZ) reported first-quarter 2025 adjusted earnings of 4.51. This miss was largely due to higher operating expenses incurred during the quarter. Earnings declined 36% year over year.Total revenues declined 0.5% year over year to 981 million, attributed to the soft sales performance of its marketed products. (Find the latest EPS es ...